<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04899141</url>
  </required_header>
  <id_info>
    <org_study_id>EPIC26-VELAZQUEZ</org_study_id>
    <nct_id>NCT04899141</nct_id>
  </id_info>
  <brief_title>Prospective Registry of ihtDEStiny® Coronary Stent in Regular PCI Practice</brief_title>
  <acronym>VELAZQUEZ</acronym>
  <official_title>Prospective Registry of ihtDEStiny® Coronary Stent in Regular PCI Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación EPIC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación EPIC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective registry intended to evaluate clinical outcomes of ihtDEStiny drug eluting&#xD;
      coronary stent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective registry intended to evaluate clinical outcomes of ihtDEStiny drug eluting&#xD;
      coronary stent use in real-world percutaneous coronary intervention&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>2 years</time_frame>
    <description>Rate of target lesion failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>2 years</time_frame>
    <description>Death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Target vessel myocardial infarction</measure>
    <time_frame>2 years</time_frame>
    <description>Target vessel myocardial infarction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Target lesion revascularization (TLR)</measure>
    <time_frame>2 years</time_frame>
    <description>Target lesion revascularization (TLR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular Death</measure>
    <time_frame>2 years</time_frame>
    <description>Cardiovascular Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>2 years</time_frame>
    <description>Stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>2 years</time_frame>
    <description>Composite event of cardiovascular (CV) death, target vessel myocardial infarction (MI) and target vessel revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiovascular Event (MACE)</measure>
    <time_frame>2 years</time_frame>
    <description>Composite event of cardiovascular (CV) death, non-fatal myocardial infarction (MI) and non-fatal stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Oriented Composite Event</measure>
    <time_frame>2 years</time_frame>
    <description>Composite event of death, non-fatal myocardial infarction (MI), non-fatal stroke or any revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe BARC Bleeding</measure>
    <time_frame>2 years</time_frame>
    <description>BARC Bleeding ≥3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>During procedure</time_frame>
    <description>residual coronary stenosis&lt;50%, normal coronary flow and absence of coronary dissection ≥C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>3 days</time_frame>
    <description>Device success and absence of PCI complication (periprocedural MI, coronary perforation, urgent CABG or death) or revascularization within 3 days</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">375</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Coronary Artery Disease</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous Coronary Intervention</intervention_name>
    <description>stenting with the ihtDEStiny® sirolimus eluting stent</description>
    <arm_group_label>Coronary Artery Disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with all inclusion criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years old&#xD;
&#xD;
          -  PCI and stent implantation indication according to ESC Myocardial Revascularization&#xD;
             Guidelines&#xD;
&#xD;
          -  At least 1 stenosis at native coronary anatomy, in a 2-4mm vessel size, that could be&#xD;
             treated with 1 or more ihtDEStiny® drug eluting stent&#xD;
&#xD;
          -  Informed consent previous to PCI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal to participate in the study&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Other DES implantation during index PCI, or 30 days before of after index PCI&#xD;
&#xD;
          -  PCI at surgical grafts&#xD;
&#xD;
          -  PCI for in-stent restenosis&#xD;
&#xD;
          -  Killip class 3-4 Acute Coronary Syndromes (ACS)&#xD;
&#xD;
          -  High bleeding risk with dual antiplatelet intolerance for at least 3 months (or 6&#xD;
             months for ACS PCI)&#xD;
&#xD;
          -  Allergy or hypersensitivity to sirolimus&#xD;
&#xD;
          -  Patients requiring surgery (cardiac or non-cardiac) in the next 3 months after index&#xD;
             PCI&#xD;
&#xD;
          -  Patients with life expectancy &lt;2 years&#xD;
&#xD;
          -  Patients included in other trials or clinical studies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>FUNDACION EPIC</last_name>
    <phone>0034987876135</phone>
    <phone_ext>6</phone_ext>
    <email>iepic@fundacionepic.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>JOSE ANTONIO LINARES VICENTE, MD,PhD</last_name>
    <email>jalinares@asociacionepic.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>de la Torre Hernández JM, Ocaranza Sanchez R, Santas Alvarez M, Pinar Bermudez E, Hurtado Martinez JA, Garcia Del Blanco B, Otaegui I, Fernandez Nofrerias E, Carrillo Suarez X, Sainz Laso F, Casanova Sandoval JM, Rivera Aguilar PK, Cid B, Trillo R, Lozano Ruiz-Poveda F, Peral Disdier V, Telleria M, Torres A, Sanchis J, Oliva X, Freixa X, Sadaba Sagredo M, Moreu J, Hernández F. Comparison of One-Year Outcomes Between the ihtDEStiny BD Stent and the Durable-Polymer Everolimus- and Zotarolimus-Eluting Stents: A Propensity-Score-Matched Analysis. Cardiovasc Revasc Med. 2021 Oct;31:1-6. doi: 10.1016/j.carrev.2020.09.046. Epub 2020 Oct 3.</citation>
    <PMID>33060037</PMID>
  </reference>
  <reference>
    <citation>de la Torre Hernandez JM, Otaegui I, Subinas A, Gomez-Menchero A, Moreno R, Rondan J, Muñoz-Garcia E, Sainz-Laso F, Garcia Del Blanco B, Rumoroso JR, Diaz JF, Berenguer A, Gomez-Lara J, Zueco J. First-in-Man Evaluation of a Sirolimus-Eluting Stent With Abluminal Fluoropolymeric/Triflusal Coating With Ultrathin Struts by OCT at 9 Months' Follow-Up: The PROMETHEUS Study. Cardiovasc Revasc Med. 2021 Nov;32:18-24. doi: 10.1016/j.carrev.2020.12.025. Epub 2020 Dec 29.</citation>
    <PMID>33386256</PMID>
  </reference>
  <reference>
    <citation>Buiten RA, Ploumen EH, Zocca P, Doggen CJM, Danse PW, Schotborgh CE, Scholte M, van Houwelingen KG, Stoel MG, Hartmann M, Tjon Joe Gin RM, Somi S, Linssen GCM, Kok MM, von Birgelen C. Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT. JACC Cardiovasc Interv. 2019 Sep 9;12(17):1650-1660. doi: 10.1016/j.jcin.2019.04.054. Epub 2019 Aug 14.</citation>
    <PMID>31422087</PMID>
  </reference>
  <reference>
    <citation>El-Hayek G, Bangalore S, Casso Dominguez A, Devireddy C, Jaber W, Kumar G, Mavromatis K, Tamis-Holland J, Samady H. Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug-Eluting Stents. JACC Cardiovasc Interv. 2017 Mar 13;10(5):462-473. doi: 10.1016/j.jcin.2016.12.002. Review.</citation>
    <PMID>28279314</PMID>
  </reference>
  <reference>
    <citation>Iantorno M, Lipinski MJ, Garcia-Garcia HM, Forrestal BJ, Rogers T, Gajanana D, Buchanan KD, Torguson R, Weintraub WS, Waksman R. Meta-Analysis of the Impact of Strut Thickness on Outcomes in Patients With Drug-Eluting Stents in a Coronary Artery. Am J Cardiol. 2018 Nov 15;122(10):1652-1660. doi: 10.1016/j.amjcard.2018.07.040. Epub 2018 Sep 8. Review.</citation>
    <PMID>30292330</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Drug Eluting Stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

